Recovery of urothelial mediator release but prolonged elevations in interleukin-8 and nitric oxide secretion following mitomycin C treatment

Sung Hyun Kang, Russ Chess-Williams, Shailendra Anoopkumar-Dukie, Catherine McDermott

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)

Abstract

Intravesical mitomycin C (MMC) is commonly used to treat bladder cancer but is associated with local adverse effects. Here, we investigate the effects of MMC on release of urothelial mediators and production of inflammatory cytokines. Recovery and the effects of repeat treatment were also investigated. Urothelial cells were treated with MMC for 2 h at 37 °C. Immediately, 24 h and 7 days following MMC treatment, effects were assessed in terms of changes in ATP, acetylcholine and PGE2 release, and the presence of inflammatory cytokines and nitric oxide in incubation medium. Endpoints were also assessed 7 days after repeat MMC treatment. Immediately following MMC treatment at the clinical concentration (2 mg/mL), stretch-induced ATP release was significantly decreased, basal acetylcholine release was enhanced, while basal PGE2 was depressed and response to stretch increased. Twenty-four hours after treatment, basal acetylcholine was significantly increased ([MMC] ≥0.0002 mg/mL) and basal PGE2 enhanced (0.02 mg/mL). A 326-fold increase in interleukin-8 secretion and significant increase in nitric oxide release were also detected at 24 h. One week after single and repeat MMC treatment, urothelial ATP, acetylcholine and PGE2 had recovered while the increase in nitric oxide and interleukin-8 was still evident. These results indicate that urothelial mediator release is affected by MMC treatment with full recovery by 1 week. However, a concurrent increase in secretion of the inflammatory cytokine interleukin-8 and nitric oxide was also detected 24 h following treatment, which were still evident after the recovery period. These changes may play a role in the local adverse effects associated with intravesical MMC treatment.

Original languageEnglish
Pages (from-to)781-791
Number of pages11
JournalNaunyn-Schmiedeberg's Archives of Pharmacology
Volume388
Issue number7
DOIs
Publication statusPublished - 22 Jul 2015

Fingerprint

Mitomycin
Interleukin-8
Nitric Oxide
Dinoprostone
Acetylcholine
Adenosine Triphosphate
Cytokines
Urinary Bladder Neoplasms

Cite this

@article{c66b4e0c10a9409497d827cc8867988f,
title = "Recovery of urothelial mediator release but prolonged elevations in interleukin-8 and nitric oxide secretion following mitomycin C treatment",
abstract = "Intravesical mitomycin C (MMC) is commonly used to treat bladder cancer but is associated with local adverse effects. Here, we investigate the effects of MMC on release of urothelial mediators and production of inflammatory cytokines. Recovery and the effects of repeat treatment were also investigated. Urothelial cells were treated with MMC for 2 h at 37 °C. Immediately, 24 h and 7 days following MMC treatment, effects were assessed in terms of changes in ATP, acetylcholine and PGE2 release, and the presence of inflammatory cytokines and nitric oxide in incubation medium. Endpoints were also assessed 7 days after repeat MMC treatment. Immediately following MMC treatment at the clinical concentration (2 mg/mL), stretch-induced ATP release was significantly decreased, basal acetylcholine release was enhanced, while basal PGE2 was depressed and response to stretch increased. Twenty-four hours after treatment, basal acetylcholine was significantly increased ([MMC] ≥0.0002 mg/mL) and basal PGE2 enhanced (0.02 mg/mL). A 326-fold increase in interleukin-8 secretion and significant increase in nitric oxide release were also detected at 24 h. One week after single and repeat MMC treatment, urothelial ATP, acetylcholine and PGE2 had recovered while the increase in nitric oxide and interleukin-8 was still evident. These results indicate that urothelial mediator release is affected by MMC treatment with full recovery by 1 week. However, a concurrent increase in secretion of the inflammatory cytokine interleukin-8 and nitric oxide was also detected 24 h following treatment, which were still evident after the recovery period. These changes may play a role in the local adverse effects associated with intravesical MMC treatment.",
author = "Kang, {Sung Hyun} and Russ Chess-Williams and Shailendra Anoopkumar-Dukie and Catherine McDermott",
year = "2015",
month = "7",
day = "22",
doi = "10.1007/s00210-015-1092-7",
language = "English",
volume = "388",
pages = "781--791",
journal = "Naunyn-Schmiedeberg's Archives of Pharmacology",
issn = "0028-1298",
publisher = "Springer",
number = "7",

}

Recovery of urothelial mediator release but prolonged elevations in interleukin-8 and nitric oxide secretion following mitomycin C treatment. / Kang, Sung Hyun; Chess-Williams, Russ; Anoopkumar-Dukie, Shailendra; McDermott, Catherine.

In: Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 388, No. 7, 22.07.2015, p. 781-791.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Recovery of urothelial mediator release but prolonged elevations in interleukin-8 and nitric oxide secretion following mitomycin C treatment

AU - Kang, Sung Hyun

AU - Chess-Williams, Russ

AU - Anoopkumar-Dukie, Shailendra

AU - McDermott, Catherine

PY - 2015/7/22

Y1 - 2015/7/22

N2 - Intravesical mitomycin C (MMC) is commonly used to treat bladder cancer but is associated with local adverse effects. Here, we investigate the effects of MMC on release of urothelial mediators and production of inflammatory cytokines. Recovery and the effects of repeat treatment were also investigated. Urothelial cells were treated with MMC for 2 h at 37 °C. Immediately, 24 h and 7 days following MMC treatment, effects were assessed in terms of changes in ATP, acetylcholine and PGE2 release, and the presence of inflammatory cytokines and nitric oxide in incubation medium. Endpoints were also assessed 7 days after repeat MMC treatment. Immediately following MMC treatment at the clinical concentration (2 mg/mL), stretch-induced ATP release was significantly decreased, basal acetylcholine release was enhanced, while basal PGE2 was depressed and response to stretch increased. Twenty-four hours after treatment, basal acetylcholine was significantly increased ([MMC] ≥0.0002 mg/mL) and basal PGE2 enhanced (0.02 mg/mL). A 326-fold increase in interleukin-8 secretion and significant increase in nitric oxide release were also detected at 24 h. One week after single and repeat MMC treatment, urothelial ATP, acetylcholine and PGE2 had recovered while the increase in nitric oxide and interleukin-8 was still evident. These results indicate that urothelial mediator release is affected by MMC treatment with full recovery by 1 week. However, a concurrent increase in secretion of the inflammatory cytokine interleukin-8 and nitric oxide was also detected 24 h following treatment, which were still evident after the recovery period. These changes may play a role in the local adverse effects associated with intravesical MMC treatment.

AB - Intravesical mitomycin C (MMC) is commonly used to treat bladder cancer but is associated with local adverse effects. Here, we investigate the effects of MMC on release of urothelial mediators and production of inflammatory cytokines. Recovery and the effects of repeat treatment were also investigated. Urothelial cells were treated with MMC for 2 h at 37 °C. Immediately, 24 h and 7 days following MMC treatment, effects were assessed in terms of changes in ATP, acetylcholine and PGE2 release, and the presence of inflammatory cytokines and nitric oxide in incubation medium. Endpoints were also assessed 7 days after repeat MMC treatment. Immediately following MMC treatment at the clinical concentration (2 mg/mL), stretch-induced ATP release was significantly decreased, basal acetylcholine release was enhanced, while basal PGE2 was depressed and response to stretch increased. Twenty-four hours after treatment, basal acetylcholine was significantly increased ([MMC] ≥0.0002 mg/mL) and basal PGE2 enhanced (0.02 mg/mL). A 326-fold increase in interleukin-8 secretion and significant increase in nitric oxide release were also detected at 24 h. One week after single and repeat MMC treatment, urothelial ATP, acetylcholine and PGE2 had recovered while the increase in nitric oxide and interleukin-8 was still evident. These results indicate that urothelial mediator release is affected by MMC treatment with full recovery by 1 week. However, a concurrent increase in secretion of the inflammatory cytokine interleukin-8 and nitric oxide was also detected 24 h following treatment, which were still evident after the recovery period. These changes may play a role in the local adverse effects associated with intravesical MMC treatment.

UR - http://www.scopus.com/inward/record.url?scp=84932193624&partnerID=8YFLogxK

U2 - 10.1007/s00210-015-1092-7

DO - 10.1007/s00210-015-1092-7

M3 - Article

VL - 388

SP - 781

EP - 791

JO - Naunyn-Schmiedeberg's Archives of Pharmacology

JF - Naunyn-Schmiedeberg's Archives of Pharmacology

SN - 0028-1298

IS - 7

ER -